These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 21052868)

  • 21. [Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450].
    Saldaña-Cruz AM; Sánchez-Corona J; Márquez de Santiago DA; García-Zapién AG; Flores-Martínez SE
    Rev Neurol; 2013 May; 56(9):471-9. PubMed ID: 23629749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADME pharmacogenetics: future outlook for Russia.
    Mirzaev KB; Fedorinov DS; Ivashchenko DV; Sychev DA
    Pharmacogenomics; 2019 Jul; 20(11):847-865. PubMed ID: 31368406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs.
    Anderson GD
    Neurology; 2004 Nov; 63(10 Suppl 4):S3-8. PubMed ID: 15557548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.
    Ingelman-Sundberg M; Rodriguez-Antona C
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1563-70. PubMed ID: 16096104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
    Fatunde OA; Brown SA
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [From the Viewpoint of Drug Metabolism Research].
    Nakajima M
    Yakugaku Zasshi; 2017; 137(6):697-705. PubMed ID: 28566576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
    Manikandan P; Nagini S
    Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics and antipsychotic treatment response.
    Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
    Holstein A; Beil W; Kovacs P
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1549-63. PubMed ID: 23153186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
    Bai JP
    Drug Metab Pharmacokinet; 2010; 25(1):62-71. PubMed ID: 20208389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacogenomics. What is relevant for the internal medicine specialist?].
    Krüth P; Wehling M
    Internist (Berl); 2003 Dec; 44(12):1524-30. PubMed ID: 14689195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical approach to pharmacogenetics.
    de Graaff LC; van Schaik RH; van Gelder T
    Neth J Med; 2013 Apr; 71(3):145-52. PubMed ID: 23712814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
    Camilleri M
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():40-5. PubMed ID: 17620087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of Pharmacogenomics to the Management of IBS.
    Camilleri M
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):584-594. PubMed ID: 29709540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Venkatakrishnan K; Pickard MD; von Moltke LL
    Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.